Summary
Albert Sabin (1906—1993) was a Polish-born American virologist who developed the oral polio vaccine that eventually displaced Jonas Salk’s injectable version across most of the world. Working at the University of Cincinnati, Sabin maintained throughout the 1950s that only a live, attenuated virus could produce durable immunity, a conviction he held with an intensity that shaped both the science and the politics of polio research. Unable to conduct large-scale trials in the United States, he arranged field tests in the Soviet Union involving ten million children, a Cold War collaboration that provided the epidemiological evidence needed for American licensing. His vaccine, administered on sugar cubes during the community drives of 1962 and 1963, briefly became synonymous with polio prevention, though the United States ultimately returned to Salk’s killed-virus formulation in 2000.
Scientific Position and Temperament
By the late 1940s, three researchers were simultaneously pursuing a polio vaccine: Jonas Salk at the University of Pittsburgh, Albert Sabin at the University of Cincinnati, and Hilary Koprowski at Lederle Laboratories in New York.(Oshinsky, 2005) The competition among them was shaped by the National Foundation for Infantile Paralysis, which controlled most research funding and therefore much of the strategic direction of American polio science.
Sabin’s professional character combined genuine scientific brilliance with a fierce competitive intelligence he made no effort to conceal. Oshinsky describes his intellectual arrogance as a defining trait: Sabin was certain that the killed-virus approach was scientifically bankrupt and expressed his contempt for Salk’s work with a directness that left few colleagues neutral.(Oshinsky, 2005)
His position rested on a theoretical argument that most virologists shared: durable immunity required infection with a living organism, and a killed-virus preparation could produce only temporary protection.(Oshinsky, 2005)
At the January 1953 Hershey meeting of the NFIP Immunization Committee, Salk presented preliminary data from trials at the Watson Home and Polk School.(Oshinsky, 2005) The results were considerable, but the committee was unmoved.(Oshinsky, 2005) Sabin dismissed the data as preliminary; John Enders called for more animal testing.(Oshinsky, 2005) The meeting ended without endorsing field trials.(Oshinsky, 2005)
Basil O’Connor, head of the National Foundation for Infantile Paralysis, responded by sidelining Sabin entirely: he kept Sabin and other critics off the Vaccine Advisory Committee, which was charged with determining how and when to mass-test Salk’s preparation, and moved forward without their input.(Oshinsky, 2005) That entanglement of caution and self-interest ran through Sabin’s public role in the early 1950s. Oshinsky notes that the boundary between scientific caution and self-interested obstruction was persistently blurred in the polio vaccine competition. Sabin’s warnings about premature trials were simultaneously legitimate and strategically convenient, and he was widely viewed within the research community as treating polio research as a zero-sum competition.(Oshinsky, 2005)
The Rivalry with Salk
At the 1951 NFIP immunization roundtable, Albert Sabin publicly condemned Hilary Koprowski’s testing on institutionalized children as unethical.(Oshinsky, 2005) Later events would reveal that Sabin was not opposed to such testing, as he himself later proposed an almost identical experiment.(Oshinsky, 2005)
Sabin was among the scientists excluded from a February 1953 Waldorf-Astoria briefing for journalists and health officials at which Salk presented his results.(Oshinsky, 2005) A letter advised against being pushed into premature field tests, urging that everything be carefully worked out before proceeding on a public scale.(Oshinsky, 2005)
The rivalry never resolved into reconciliation. The two men remained estranged for the rest of their lives, and the institutional consequences of their competition shaped American vaccine policy for decades.
Human Testing and Ethical Contradictions
In 1954 and 1955, Sabin conducted trials of his live-virus oral vaccine on thirty adult male prisoners at the federal reformatory in Chillicothe, Ohio, paying each $25 for participation.(Oshinsky, 2005) The ethical contradictions embedded in this choice were not lost on contemporaries. In 1951, Sabin had been among the most vocal critics of Koprowski’s unannounced human experiments with live-virus vaccine strains. Koprowski had tested his preparation on himself and a laboratory assistant in 1948, then arranged administration to seventeen residents of a New York State school for the mentally disabled without obtaining parental consent or informing any oversight committee.(Oshinsky, 2005) His own use of institutionalized prisoners, whose capacity for genuinely voluntary consent was constrained by their circumstances, placed his earlier condemnations in an uncomfortable light.
The irony of Sabin’s own use of prisoners was not lost on those who remembered his earlier harsh condemnation of Koprowski’s unannounced human testing.(Oshinsky, 2005)
The Soviet Trials
Unable to secure the large-scale trial population that American regulatory and institutional structures could not provide, Sabin found his proving ground abroad. Working with Mikhail Chumakov at the Soviet Academy of Medical Sciences, he arranged for his three vaccine strains to be tested on ten million Soviet children in the late 1950s, a collaboration made possible by a Cold War scientific relationship between the two men that crossed political lines without resolving them.(Oshinsky, 2005)
The scale of the Soviet trials was decisive for Sabin’s case. No American institution could have approved or organized trials of that magnitude in that period, and the epidemiological data they produced was qualitatively different from anything available from smaller studies. The Cold War context was not incidental: an American scientist, unable to conduct large trials at home, used the Soviet Union to build the evidence base for a vaccine he intended to bring back to the United States.(Oshinsky, 2005)
To verify the results, the World Health Organization sent Dorothy Horstmann of Yale to evaluate the 1959 Soviet Sabin vaccine trials.(Oshinsky, 2005) Horstmann returned with a measured but positive assessment: the trials had been conducted properly, and the results were genuine.(Oshinsky, 2005) Her endorsement provided the Western scientific legitimacy that Soviet data alone could not command.(Oshinsky, 2005) [GAP: The paragraph originally claimed this moved the argument onto ground American regulators could accept, but the cited card only mentions Western scientific legitimacy and eventual WHO endorsement.]
The Live-Virus Vaccine and Its Adoption
The American Medical Association endorsed Sabin’s oral polio vaccine at its annual meeting in July 1961, before federal licensing had been completed. The Department of Health, Education, and Welfare licensed Type I of the Sabin vaccine in September 1961.(Oshinsky, 2005)
The community oral vaccination drives of 1962–1963, nicknamed “Sabin Sundays,” administered the three vaccine types in sequence on successive Sundays at firehouses, schools, and community centers.(Oshinsky, 2005) The drives achieved high population coverage through the convenience and drama of swallowing a sugar cube rather than receiving an injection.(Oshinsky, 2005)
By 1963, the oral Sabin vaccine had largely supplanted Salk’s injectable vaccine in American public health practice.(Oshinsky, 2005) The man who had saved millions of children from polio watched as his vaccine was supplanted by his rival’s.(Oshinsky, 2005) Oshinsky describes this as a professional humiliation that Salk never fully accepted.(Oshinsky, 2005)
Death and the Return to Salk
Albert Sabin died on March 3, 1993, from heart failure. Jonas Salk died on June 23, 1995, also from heart failure. The two men had never reconciled; the rivalry that had defined their careers ended as it had lived, in silence.(Oshinsky, 2005)
The return to Salk was policy, not sentiment. In 2000, the Centers for Disease Control reversed the 1963 shift and reinstated the killed-virus injectable vaccine as the exclusive recommended formulation for American children. The reason was specific: wild poliovirus had been eliminated from the Western Hemisphere in 1991, which meant that the only remaining polio cases in the United States were caused by the Sabin vaccine itself. Vaccine-associated paralytic polio occurred at an estimated rate of approximately one case per 750,000 first doses, a small but measurable and now preventable risk.(Oshinsky, 2005) Where transmission needed to be interrupted in a population that still carried the virus, Sabin’s live formulation retained its advantages. Where the wild virus was absent, those advantages disappeared and the residual risk remained.
Global Legacy
The oral vaccine’s most consequential chapter was not in the United States but in the developing world. In 1987, when the World Health Organization launched its global polio eradication initiative, approximately 300,000 children were being paralyzed by poliovirus each year. The oral Sabin vaccine, cheap to produce, stable without refrigeration in many formulations, and administrable without medical personnel or needles, was the instrument of the campaign. By 2000 the annual number of paralytic cases had fallen below 2,000, a reduction of more than 99 percent.(Oshinsky, 2005) Whatever the complications of Sabin’s biography, the scale of that outcome is not in dispute.
Scholarly Assessment
Sabin was a rival of Jonas Salk who viewed polio research as a zero-sum game with no room for two successful vaccines.(Oshinsky, 2005) He had shown no interest in helping Salk in the past and was widely regarded as believing that for him to win, others had to lose.(Oshinsky, 2005)
The prison trials and the Soviet collaboration both illustrate the tensions Oshinsky identifies. Sabin condemned Koprowski’s unannounced human experiments in 1951 and then used institutionalized prisoners in 1954 without apparent awareness of the inconsistency.(Oshinsky, 2005) He built his scientific case through a Cold War partnership that American institutions could not have sanctioned and that depended on access to Soviet children whose parents had no meaningful alternative to participation.(Oshinsky, 2005) These are not damning anomalies in an otherwise clean career; they are characteristic features of how large-scale vaccine development actually proceeded in the mid-twentieth century, under conditions that allowed for very little of the procedural clarity that later regulatory frameworks would impose.
What Oshinsky does not do is reduce Sabin to a villain. The scientific argument for live-virus vaccine was legitimate, the global application was genuinely consequential, and the eventual return to Salk’s formulation was a product of success rather than failure: the oral vaccine did its work well enough that the risk it carried eventually outweighed the protection it offered in settings where the wild virus was gone. The life’s work held together. The man behind it was harder to assess.